Sarclisa (isatuximab-irfc) for the Treatment of Multiple Myeloma
Sarclisa was approved by the US Food and Drug Administration (FDA) in March 2020. Credit: Sanofi-Aventis.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more